Overview

Study of Velcade and Thalidomide in Patients With Myelodysplasia

Status:
Terminated
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what the maximal tolerated dose of Velcade can be given with thalidomide in patients with myelodysplasia.
Phase:
Phase 1
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Treatments:
Bortezomib
Thalidomide